Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model
Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model
复制标题
DOI：
10.1016/j.antiviral.2018.04.014
复制
发表时间：
2018-06-01
影响因子：
7.6
通讯作者：
Haynes, Lia M.
中科院分区：
文献类型：
--
作者：
Caidi, Hayat;Miao, Congrong;Haynes, Lia M.
RSV仍然是疫苗和抗病毒药物开发的高度优先事项。不幸的是，没有安全有效的RSV疫苗可用，治疗选择有限。在过去的十年里，一些研究集中在RSV G蛋白在病毒进入、病毒中和和RSV介导的病理中的作用。抗G鼠单抗(MAb)131-2G治疗已被证明比商业人源化抗RSV F蛋白单抗(Palivizumab)更快地减少RSV感染小鼠的体重减轻、支气管肺泡灌洗(BAL)细胞数量、呼吸道反应性和Th2型细胞因子的产生。在本研究中，我们在BALB/c小鼠模型上检测了两种人源性抗RSV G单抗2B11和3D3对RSV的预防和治疗作用。两种抗G单抗均可减少病毒载量、白细胞浸润和无细胞BAL上清液中干扰素-γ和IL-4的表达，强调了抗G单抗作为抗炎和抗病毒策略的潜力。
RSV continues to be a high priority for vaccine and antiviral drug development. Unfortunately, no safe and effective RSV vaccine is available and treatment options are limited. Over the past decade, several studies have focused on the role of RSV G protein on viral entry, viral neutralization, and RSV-mediated pathology. Anti-G murine monoclonal antibody (mAb) 131-2G treatment has been previously shown to reduce weight loss, bronchoalveolar lavage (BAL) cell number, airway reactivity, and Th2-type cytokine production in RSV-infected mice more rapidly than a commercial humanized monoclonal antibody (mAb) against RSV F protein (Palivizumab). In this study, we have tested two human anti-RSV G mAbs, 2B11 and 3D3, by both prophylactic and therapeutic treatment for RSV in the BALB/c mouse model. Both anti-G mAbs reduced viral load, leukocyte infiltration and IFN-gamma and IL-4 expression in cell-free BAL supernatants emphasizing the potential of anti-G mAbs as anti-inflammatory and antiviral strategies.